Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy

Mehdizadeh, Mehrzad; Rouhani, Hasti; Sepehri, Nima; Varshochian, Reyhaneh; Ghahremani, Mohammad Hossein; Amini, Mohsen; Gharghabi, Mehdi; Ostad, Seyed Nasser; Atyabi, Fatemeh; Baharian, Azin; Dinarvand, Rassoul

doi:10.1080/21691401.2016.1178130

Cited by 48 publications

(36 citation statements)

References 33 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that localized presentation of SA-FasL on islets supported long-term function on the scaffold, we subsequently investigated the immobilization of SA-FasL to the scaffold as a means to minimize the cellular manipulation prior to transplantation. Biotin decorated PLG particles have been reported for targeted drug delivery to cancer cells [48]. Manipulating the scaffold to present SA-FasL would eliminate the steps needed for direct islet engineering, and as such save time and overcome potential undesired effects associated with engineering process, such as cell fragmentation.…”

Section: Discussionmentioning

confidence: 99%

Localized immune tolerance from FasL-functionalized PLG scaffolds

et al. 2019

View full text Add to dashboard Cite

Intraportal allogeneic islet transplantation has been demonstrated as a potential therapy for type 1 diabetes (T1D). The placement of islets into the liver and chronic immunosuppression to control rejection are two major limitations of islet transplantation. We hypothesize that localized immunomodulation with a novel form of FasL chimeric with streptavidin, SA-FasL, can provide protection and long-term function of islets at an extrahepatic site in the absence of chronic immunosuppression. Allogeneic islets modified with biotin and engineered to transiently display SA-FasL on their surface showed sustained survival following transplantation on microporous scaffolds into the peritoneal fat in combination with a short course (15 days) of rapamycin treatment. The challenges with modifying islets for clinical translation motivated the modification of scaffolds with SA-FasL as an off-the-shelf product. Poly(lactide-co-glycolide) (PLG) was conjugated with biotin and fabricated into particles and subsequently formed into microporous scaffolds to allow for rapid and efficient conjugation with SA-FasL. Biotinylated particles and scaffolds efficiently bound SA-FasL and induced apoptosis in cells expressing Fas receptor (FasR). Scaffolds functionalized with SA-FasL were subsequently seeded with allogeneic islets

show abstract

Section: Discussionmentioning

confidence: 99%

Localized immune tolerance from FasL-functionalized PLG scaffolds

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Hence, the cation number indicates a positive correlation with the gene transfer rate [ 29 ]. Concomitantly, biotin can couple with nanoparticles and facilitate their transfer to the cells in the presence of the targeting gene, which is considered a safe and effective targeting gene transfection method [ 30 ]. This occurs due to the binding effect of biotin with the corresponding biotin receptor on the cell surface.…”

Section: Discussionmentioning

confidence: 99%

Anti-cancer efficacy of biotinylated chitosan nanoparticles in liver cancer

Cheng

Zhu

Li³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The present study investigated the synthesis of biotinylated chitosan (Bio-CS) from chitosan using a nanomaterial skeleton with biotin and the successful targeting of the formulation in liver cancer cells. Bio-CS was validated by fourier transformed infrared spectroscopy and hydrogen-1 nuclear magnetic resonance spectroscopy. Bio-CS and plasmid DNA were used to construct Bio-CS/plasmid DNA nanoparticles according to the optimal molar ratio of 1:1 and the optimal pH-value of 5.5. Under these conditions, the parameters mean particle size, potential, encapsulation rate and drug loading, were 82.9 nm, +21.8 mV, 85.7% and 35.4%, respectively. Bio-CS exhibited an apparent liver cancer targeting effect in vitro and in vivo, as demonstrated by confocal laser scanning, green fluorescent protein transfection, and in vivo imaging assays. In addition, the Bio-CS/plasmid DNA nanoparticles significantly increased the survival period of the orthotropic liver cancer mouse model compared with the plasmid DNA, with no apparent side effects on the cells. Bio-CS nanomaterials stimulated an immune response in hepatoma cells via increased expression of GM-CSF, IL-21 and Rae-1 markers. The data suggest that Bio-CS increased the inhibition of liver cancer cell proliferation in vitro and the activation of the cellular immunity in vivo.

show abstract

“…In the same way, 7-ethyl-10-hydroxycamptothecin (SN-38) was successfully loaded into PLGA-PEG-biotin NPs to treat breast cancer. Compared to non-biotin conjugated NPs, these conjugated NPs increased the in vivo antitumor drug efficacy [125,126].…”

Section: Binding By Adapter Moleculesmentioning

confidence: 99%

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review.

show abstract

Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy

Cited by 48 publications

References 33 publications

Localized immune tolerance from FasL-functionalized PLG scaffolds

Localized immune tolerance from FasL-functionalized PLG scaffolds

Anti-cancer efficacy of biotinylated chitosan nanoparticles in liver cancer

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

Contact Info

Product

Resources

About